XSUNX - Neubewertung oder Totalverlust? - 500 Beiträge pro Seite

[LeoSchnee]

CEO Djokovich liefert beständig News.

https://xsunx.com/category/news/

Ist hier ein Rebound in Sicht, oder geht da nichts mehr?

Und, wo sind die heißen Teile noch handelbar - Consors blockt derzeit da MicroCap.

[webmimi]

Antwort auf Beitrag Nr.: 60.237.676 von LeoSchnee am 30.03.19 20:45:11

... ob hier noch was geht - zweifelhaft. Bei LYNX sind sie noch handelbar.

[LeoSchnee]

XsunX, Inc. Changes Name to NovAccess Global Inc.

Name Change, Reverse Stock Split, and Other Planned Corporate Actions Highlight Focus on Enhancing Shareholder Value

CLEVELAND, OH / ACCESSWIRE / August 26, 2020 / NovAccess Global Inc. (OTC PINK:XSNXD), today effectuated a 1-for-1,000 reverse stock split in conjunction with its new name, in order to prepare for the business model being implemented by it's new Chairman of the Board, Dan Martin.

Mr. Martin purchased a controlling preferred interest in XsunX in June, 2020. The Company is coming off a decade of steady business performance, but with limited returns in the public market for its shareholders. Since his takeover, the Company's stock and market cap have appreciated by several hundred percent, a sign that the market is enthusiastic about these and other forthcoming changes.

"While the name change and reverse stock split actions are important and foundational, I am even more thrilled to move forward with the true value that will be achieved with developments detailed in the Company's filings with the Securities and Exchange Commission. In particular, the pending acquisition of StemVax Therapeutics from Innovest Global, the anticipated nomination of new executives, and the brand launch will truly position NovAccess for a successful, long-term business that improves lives and brings novel technologies to market.

Mr. Martin is the founder and Chairman of the Board of Innovest Global, Inc. (OTC PINK:IVST). Innovest launched in 2017 with $50,000 in sales and had a market cap at that time of $300,000. It generated $6.5 million in sales in 2018 and $40 million in sales in 2019, and has recently expanded, providing meaningful solutions to industrial and commercial customers. It's significant stake in NovAccess upon completion of the StemVax spinout is expected to achieve significant balance sheet milestones for Innovest, required for its eventual plan to apply for NASDAQ listing.

https://www.accesswire.com/603155/XsunX-Inc-Changes-Name-to-…

[LeoSchnee]

NovAccess Global Acquires StemVax Therapeutics from Innovest Global

Acquisition Launches NovAccess Shift, Focusing on Diagnostics and Therapeutics in Cancer

CLEVELAND, OH / ACCESSWIRE / September 9, 2020 / NovAccess Global, Inc. (OTCPINK:XSNX), today announced that it has acquired 100% ownership of Pasadena-based StemVax Therapeutics from Innovest Global (OTCPINK:IVST).

StemVax is a translational biotechnology company developing novel immunotherapies for brain tumor patients, featuring recently approved United States patent #US9764014B2. The patent is granted under the category of "Cancer Antigens" and related to the "treatment of cancer using vaccination therapy".

StemVax Glioblast (SVX-GB) is a cancer vaccine, which is a medication that stimulates or restores the immune system's ability to fight an existing cancer by strengthening the body's natural defenses against the cancer cells. It is a meaningful technology which could significantly improve the quality of life and prognosis for the many people who suffer from brain tumors. More information can be found at www.stemvax.com.

"This acquisition is a milestone event for NovAccess, marking the foundation of our growing platform Company," said Dan Martin, NovAccess Founder and Chairman of the Board of Directors. "With this acquisition complete, we will onboard the StemVax team, launch their brand, and work towards the commercialization of StemVax's life-changing technologies. This is truly the beginning of an effort that encompasses the lifelong work of some of the most talented and incredible people I've ever met. I couldn't be more humbled or thankful to welcome the StemVax team to NovAccess."

The transaction structure features the issuance of 7.5 million common restricted shares of NovAccess Global stock to Innovest Global as consideration. The disposition by Innovest allows it to direct all of its focus on its growing industrials business while retaining upside potential should NovAccess be successful in its commercialization efforts.

https://www.accesswire.com/605438/NovAccess-Global-Acquires-…

[LeoSchnee]

Innovest Global Completes Sale of StemVax Therapeutics to NovAccess Global

Innovest Global Receives 7.5 Million Shares of NovAccess Global Common Stock as Consideration for StemVax Therapeutics; Divestiture of Biotech Subsidiary Signals Renewed Focus on Growing Industrials Business

CLEVELAND, OH / ACCESSWIRE / September 10, 2020 / Innovest Global Inc. (OTC PINK:IVST), a diversified industrials company, has completed the sale of its wholly owned subsidiary, StemVax Therapeutics, to NovAccess Global (OTC PINK:XSNX) in exchange for 7.5 million shares of restricted common stock in NovAccess Global, representing approximately 75% ownership in NovAccess.

StemVax is a translational biotechnology company developing novel immunotherapies for brain tumor patients, featuring recently approved United States patent #US9764014B2. The patent is granted under the category of "Cancer Antigens" and related to the "treatment of cancer using vaccination therapy".

StemVax Glioblast (SVX-GB) is a cancer vaccine, which is a medication that stimulates or restores the immune system's ability to fight an existing cancer by strengthening the body's natural defenses against the cancer cells. It is a meaningful technology, which could significantly improve the quality of life and prognosis for the many people who suffer from brain tumors. More information can be found at www.stemvax.com.

"I am pleased to announce the divestiture of our biotech subsidiary StemVax Therapeutics to NovAccess Global, enabling us to focus on our growing industrials business while concurrently strengthening our balance sheet and retaining equity upside potential should NovAccess be successful in its commercialization efforts of StemVax's incredible technology," said Damon Mintz, Chief Executive Officer of Innovest Global. "I look forward to continued operational execution as we march towards our uplisting to the OTCQB and eventually, NASDAQ - creating sustainable value for our shareholders over the long-term."

About Innovest Global, Inc.

Innovest Global, Inc. (OTC: IVST) is a diversified industrial company applying technology and innovation to provide value-added solutions across multiple business markets. Innovest Global builds long-term shareholder value by acquiring established industrial businesses on favorable terms, realizing synergies and achieving organic growth through investments in innovative technology and business systems. For more information, please click here.


https://www.accesswire.com/605500/Innovest-Global-Completes-…" target="_blank" rel="nofollow ugc noopener">https://www.accesswire.com/605500/Innovest-Global-Completes-…